Alzheimer Disease
FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005
Published in Clinical Trials Week, April 16th, 2007
Transition Therapeutics Inc. ("Transition") (TSX: TTH) announced today that the United States Food and Drug Administration ("FDA") has granted Fast Track designation to investigational drug candidate AZD-103/ELND005, being developed in collaboration with Elan Corporation, plc. ("Elan") (NYSE: ELN) for the treatment of Alzheimer's disease. AZD-103/ELND005 is currently being evaluated in multiple Phase I clinical studies, and the companies anticipate starting Phase II clinical studies around the end of 2007.
"The decision by the FDA is very encouraging news for Alzheimer's disease patients and their families, and we believe it reflects the considerable potential for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2007-04-16)
More Articles from Clinical Trials Week
- Breast Cancer
Combining therapies can improve survival for early-stage breast cancer patients - Addiction Medicine
Catalyst Pharmaceutical Partners Reports Year-End 2006 Financial Results - Allergies
Commencement of Dosing in Pollinex Quattro Phase III Ragweed Trial - Allergies
Manhattan Pharmaceuticals Announces License Agreement and Expanded Pipeline - Alzheimer Disease
Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 1003 Alzheimer's Disease Trial - Arthritis
NicOx initiates second phase 3 study to confirm naproxcinod's efficacy and improved blood pressure profile - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
